Corgentech collaborates with Bristol-Myers Squibb to jointly develop and commercialize Corgentech’s E2F Decoy (edifoligide sodium) used to prevent vein graft failure following coronary and peripheral artery bypass graft surgery. The deal could be worth up to US$250 M.